亿帆医药(002019.SZ)：重酒石酸去甲肾上腺素注射用浓溶液获得新加坡注册批文

Core Viewpoint - Company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its pharmaceutical product, concentrated solution of racemic norepinephrine for injection, which is intended for the management of severe acute hypotension in adults [1] Group 1 - The product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1] - The approval marks a significant milestone for the company's expansion into the Singapore market [1]